

Not for release, publication or distribution in the United States, Australia, Canada or Japan.



NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL, OTHER RESTRICTIONS ARE APPLICABLE.
PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE INVESTOR RELATIONS NEWS.

Investor Relations News

Evonik is further advancing stock exchange listing

Essen, April 10, 2013. After the successful completion of two rounds of private placements in February and March of this year by the RAG Foundation and by funds advised by CVC Capital Partners, which together totaled approximately 12% of Evonik Industries AG's share capital, Evonik is further advancing its planned stock exchange listing. In this context, Deutsche Bank Aktiengesellschaft and MainFirst Bank Aktiengesellschaft have been mandated to advise on the listing of Evonik's shares on the regulated market of the Frankfurt and Luxembourg Stock Exchanges. The listings are targeted for end of April 2013.

In light of the large interest in the concluded private placements and in order to support trading liquidity in the secondary market, RAG Foundation and CVC are willing – favorable capital markets conditions provided – to offer in connection with the admission to trading additional shares of up to approximately 2% of Evonik's share capital to institutional investors. Additionally, shares may be offered by means of an over-allotment option ("Greenshoe").

About RAG Foundation

RAG Foundation is a civil-law foundation established in 2007. Its purpose is to build up Foundation assets by 2018 in order to fund long-term liabilities in German coal mining from 2019 onwards. Under the Foundation's Statutes, this objective is to be achieved by means of an initial public offering of Evonik Industries AG.

For further information on the RAG Foundation, please see <http://www.rag-stiftung.de/en/>

RAG Foundation press contact:
Barbara Müller (Acting Press Officer)
Evonik Industries AG
Tel. +49-201-177-3423
E-Mail: barbara.mueller@evonik.com

About CVC Capital Partners

CVC is one of the world's leading private equity and investment advisory firms. Founded in 1981, CVC today has a network of 21 offices and 280 employees throughout Europe, Asia and the US.

Currently, CVC manages funds on behalf of over 300 investors from North America, Europe, Asia and the Middle East, who entrust their capital to CVC for periods of 10 years or more. To date, CVC has secured commitments of

Not for release, publication or distribution in the United States, Australia, Canada or Japan.

over US\$50bn in funds from a diverse and loyal investor base, completing over 300 investments in a wide range of industries and countries across the globe, with an aggregate transaction value of around US\$167bn.

For further information, please visit www.cvc.com

Michael Iltschev
Hering Schuppener Consulting
Tel. +49-69-921874-49
Mobil: +49-151-16231325
E-Mail: miltschev@heringschuppener.com

Dr. Phoebe Kebbel
Hering Schuppener Consulting
Tel. +49-69-921874-77
Mobil: +49-173-2862110
E-Mail: pkebbel@heringschuppener.com

About Evonik Industries AG:

Evonik, the creative industrial group from Germany, is one of the world leaders in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik's corporate strategy. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik benefits specifically from its innovative prowess and integrated technology platforms.

Evonik is active in over 100 countries around the world. In fiscal 2012 more than 33,000 employees generated sales of around €13.6bn and an operating profit (adjusted EBITDA) of about €2.6bn.

Evonik Industries AG:
Tim Lange
Head of Investor Relations
Tel. +49-201-177-3150
E-Mail: tim.lange@evonik.com

Disclaimer:

These materials may not be published, distributed or transmitted in the United States, Canada, Australia or Japan. These materials do not constitute an offer of securities for sale or a solicitation of an offer to purchase securities (the "Shares") of Evonik Industries AG (the "Company") in the United States, Germany or any other jurisdiction. The Shares of the Company may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the "Securities Act"). The Shares of the Company have not been, and will not be, registered under the Securities Act.

This publication constitutes neither an offer to sell nor a solicitation to buy securities.

In the United Kingdom, this document is only being distributed to and is only directed at persons who (i) are investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the "Order") or (ii) are persons falling within Article 49(2)(a) to (d) of the Order (high net worth companies, unincorporated associations, etc.) (all such persons together being referred to as "Relevant Persons"). This document is directed only at Relevant Persons and must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this document relates is available only to Relevant Persons and will be engaged in only with Relevant Persons.

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this Investor Relations News.